News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Graffinity Pharmaceuticals GmbH And Amgen (AMGN) Enter into Drug Discovery Research Agreement


2/26/2007 2:32:04 AM

HEIDELBERG, Germany--(BUSINESS WIRE)--Graffinity Pharmaceuticals GmbH announced today that it has entered into a research collaboration with Amgen, Thousand Oaks, California. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets. Amgen will gain access to Graffinity’s proprietary fragment-based drug discovery technology which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets which play a key role in major human diseases. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES